Bone Marrow Transplantation News

Lakshmanan Krishnamurti, MD, has been appointed chief of pediatric hematology, oncology and bone marrow transplant at Yale New Haven Children’s Hospital.

Many individuals with cancer lack adequate immune defense against the measles and mumps viruses, according to a study conducted by researchers at Fred Hutchinson Cancer Research Center and published in JAMA Network Open.

The FDA granted priority review to abatacept for prevention of moderate to severe acute graft-versus-host disease among patients aged 6 years or older receiving unrelated donor hematopoietic stem cell transplantation.

Post-transplant cyclophosphamide reduced incidence of graft-versus-host disease but led to higher incidence of early cardiac events after allogeneic hematopoietic stem cell transplantation, according to study results.

Clinicians who treat blood cancers often disagree whether chimeric antigen receptor T-cell therapies are a potential replacement for hematopoietic stem cell transplant.

ASH will present honorific awards to several hematologists during this year’s ASH Annual Meeting, scheduled for Dec. 11-14.

As targeted therapies and novel treatments emerge, allogeneic hematopoietic cell transplantation has taken a backseat to immunotherapy in the treatment of lymphoma.

Navneet Majhail, MD, MS, FASTCT, has been appointed deputy physician-in-chief of blood cancers for Sarah Cannon Transplant and Cellular Therapy Network.

The FDA today approved belumosudil for treatment of patients aged 12 years or older with chronic graft-versus-host disease, according to the agent’s manufacturer.

Peter Abdelmessieh, DO, MSc, has joined the department of bone marrow transplant and cellular therapies at Fox Chase Cancer Center.